Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger ...

Pfizer (PFE) has reportedly decided to sell its entire remaining stake in BioNTech (BNTX), showing a lack of confidence in ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those who completed a 6-month follow-up, the mRNA vaccine had a relative efficacy ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

A newly developed mRNA-based flu vaccine is almost 35 per cent more effective against the most common form of influenza, ...

The new study involved taking a fresh look at the "Altamura Man," which is an exceptionally well-preserved Neanderthal ...

Moderna's $140 million investment in Norwood, Massachusetts, aims to complete its U.S. manufacturing loop, enhancing ...

For the last several months, reports about bird flu have largely quieted -- until now. In the first human bird flu case in the U.S. since February, an older adult in Washington state was hospitalized ...

Despite the success of immune checkpoint inhibitors in revolutionizing oncology, their benefits remain limited to a small ...